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1                               INTRODUCTION
Hypertrophic cardiomyopathy is a  common autosomal dominant 
cardiovascular disease .
Dynamic obstruction to LV outflow  can occur under resting or 
physiologically provocable conditions in patients with HCM. various 
phenotypic and genotypic heterogeneity are observed in HCM. HCM is 
the most common genetically transmitted cardiovascular disease which 
affects 1 in 500 people. The most frequent cause of sudden cardiac 
death in young athletes is HCM1. HCM patients may have very severe 
to negligible hypertrophy.HCM patients can have  fibrosis and disarray 
of cardiac myocytes which may be minimal to extensive .
HCM patients have a natural history which may range from being 
aymptomatic to having protracted dyspnea and angina.
Sudden cardiac death may be the presenting event in some 
hypertrophic cardiomyopathy patients 2 . Hypertrophic cardiomyopathy
was reported by Teare in 1958 as ‘asymmetrical hypertrophy of the 
heart in young adults’1.
2The WHO defined cardiomyopathies as ‘diseases of different and 
often unknown etiology in which the dominant feature is cardiomegaly 
and heart failure’1. In 1980 this definition was updated as ‘heart muscles 
diseases of unknown cause’1.This differentiated HCM from heart 
muscle diseases of known etiology, such as myocarditis.
Idiopathic hypertrophic subaortic stenosis, muscular subaortic 
stenosis have been the alternate old nomenclature for hypertrophic 
obstructive cardiomyopathy2 .
In 1995, a WHO/International Society and Federation of 
Cardiology Task Force defined  HCM  as ‘left and/or right ventricular 
hypertrophy, usually asymmetric and involving the interventricular 
septum with predominant autosomal dominant inheritance involving 
sarcomeric contractile proteins’3. 
                                     
                                   
3AIM OF THE STUDY:
1.Risk stratification of patients with Hypertrophic 
Cardiomyopathy  .
2.Assessment of  Biventricular diastolic function  in  patients with 
Hypertrophic  cardiomyopathy  by pulse/tissue doppler 
echocardiographic imaging
                              
4REVIEW OF LITERATURE
HCM results  by  mutations encoding contractile proteins- β-
myosin heavy chain and myosin binding protein C , troponin T and I, 
regulatory and essential myosin light chains, titin, α-tropomyosin, α-
actin, α-myosin heavy chain, and muscle LIM protein 4.
The clinical manifestations vary among patients, from 
asymptomatic, to  heart failure.  Asymmetric hypertrophy of the 
interventricular septum, with or without left ventricular outflow tract 
obstruction is mostly diagnosed by echocardiography . We have to 
exclude other causes of hypertrophy, like hypertension, coarctation of 
aorta and aortic stenosis 5.
Athletes with physiological hypertrophy of left ventricle 
confound the diagnosis of HCM .  The prevalence of HCM is 1:500 in 
young adults.
Genetic screening of all first degree relatives is recommended. 
Most of the Mutations in HCM happen as single nucleotide substitutions 
or “missense” mutations5. 
                  
5Pathology
Severe left ventricular hypertrophy and small LV size are  gross 
features seen in HCM.
The ventricular septum is mainly hypertrophied.Hypertrophy 
may also be symmetrical or affect  posterior wall, apex or middle part of 
the LV .Asians have a prevalence of about 10 % in midventricular 
obstruction.
Involvement of right ventricle can also be found in infants and 
children .End stage dilated cardiomyopathy is seen in 5% of patients 
with HCM. Dilated cardiomyopathy found in end stage of HCM has 
widespread fibrosis, heart wall thinning and LV dilation 6. 
Raised LVEDP causes dilation of left atrium.Left atrium is also 
dilated  by diastolic relaxation abnormalities and mitral insufficiency
resulting from left ventricular outflow tract obstruction or related mitral 
valve abnormalities . The cause  of  mitral regurgitation in hypertrophic 
obstructive cardiomyopathy was originally ascribed to be due to  the 
Venturi effect created by systolic flow acceleration in the left ventricular 
outflow tract pulling the anterior mitral leaflet of mitral valve towards 
the ventricular septum causing obstruction and regurgitation7 .
6A study suggested, that at the beginning of ejection the mitral 
valve leaflets are projecting into a narrow left ventricular outflow tract 
causing fast forward flow which is the main force that drags the leaflets 
toward the septum causing obstruction8. The systolic anterior motion of 
the mitral leaflets prevents the closing of  mitral valve causing  mitral 
insufficiency.
Differences between physiologic and pathologic hypertrophy
Left Ventricular Hypertrophy
Blood pressure and volume increase results in increase in muscle 
mass of heart.cardiac myocyte replication rate is not rapid, hence its
mostly results by an enlargement in size of the cardiac myocyte than a
rise in number . 
During growth,pregnancy and in athlete’s heart physiological 
hypertrophy occurs.  Pathological cardiac hypertrophy occurs in  
hypertension. There are many differences among physiological and 
pathological myocyte hypertrophy LV hypertrophy is an adaptive 
reaction that helps the myocardium to preserve cardiac output 9. Cardiac 
remodelling involves left ventricular dilation, accumulation of collagen 
and cardiac myocyte loss. 
7Athlete’s heart is a form of physiologic cardiac hypertrophy 
which is not  associated with fibrosis or dysfunction
Concentric and  Eccentric myocyte Hypertrophy :
Physiological hypertrophy induced by exercise may be concentric 
or eccentric. Increased volume load of ventricle produces eccentric 
hypertrophy. Swimming and running are examples of endurance 
exercise which increase volume overload. In  Eccentric cardiac 
hypertrophy there is  a raise in the length of myocytes, which results in
dilation of Left Ventricle. 
Pressure overload causes concentric hypertrophy.There is left 
ventricle wall thickening and LV dilatation is mininal. Isometric 
exercises cause pressure overload . 
Stimulus for Hypertrophy Resulting From Exercise :
Exercise results in the discharge of growth factors and 
neurotransmitters, which stimulate receptors on different cell types to 
cause a biological reaction.
Insulin-like growth factor 1 concentrations are increased in 
professional football players. IGF1 levels have a good correlation with 
LV mass index and LV end-diastolic dimension index10.
8During exercise  norepinephrine a neurotransmitter is released.
Norepinephrine levels did not have a correlation with  thickness of left 
ventricle myocardium or LV cavity dimensions .Hence norepinephrine 
does not increase cardiac myocyte size
Stimuli For Pathological Hypertrophy
G Protein-Coupled Receptors
In cardiac failure patients Angiotensin II and endothelin-1 are 
upregulated. Heart myocytes release Angiotensin II and endothelin-1 
during mechanical stress . Angiotensin II and endothelin-1 signal by 
combining to G protein-coupled receptors . 
Calcineurin 
The key enzyme involved in pathological hypertrophy is 
calcineurin.In patients with hypertrophy of LV and cardiac failure 
calcineurin activity is increased,
HCM- signalling pathways
In HCM signalling pathways have not been clearly defined. It has 
been suggested that Mutant proteins in HCM could stimulate 
hypertrophy by signalling pathways included in pressure overload type 
of hypertrophy.
9Angiotensin II and endothelin I are increased in individuals with
HCM.
Hypertrophy in HCM
Hypertrophy seen mostly marked in the area of the anterior 
papillary muscle and Superior part of septum.Systolic anterior motion of 
mitral leaflet causes dynamic obstruction in HCM. Increased afterload 
stress results from dynamic obstruction.
Genetically determined  sarcomeric protein regional dysfunction 
causes abnormal stresses on nearby regions of normal myocardium..
Clinical findings
Cardiomegaly usually found on a chest x-ray, or 
electrocardiographic changes can be the initial presentation .Fatigue , 
breathlessness on exertion, palpitations, angina, syncope or sudden 
death may be the initial symptomology of presentation. 
On physical examination, in pulse there is a rise and rapid 
descent. Bulge of precordium and outward displacement of apical 
impulse are present when there is cardiac enlargement. S4 causing a 
bifid apical impulse is frequently seen.  Mid systolic murmur with 
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variable intensity is present in the left sternal border and apex
.Pansystolic murmur of mitral regurgitation may be present at the apex
The midsystolic murmurs vary with maneuvers that result in
increase or decrease left ventricle outflow gradient.
Softer Mid systolic murmurs along the left sternal border may be 
present in non-obstructive HCM also.The intensity of this murmur is 
softer. Atrial fibrillation occurs in endstage dilated hypertrophic 
cardiomyopathy. Wolff-Parkinson-White syndrome may be present in 
patients with hypertrophic cardiomyopathy rarely. 
Sudden cardiac death can be the only presenting symptom in 
hypertrophic cardiomyopathy 11 .End stage is seen in about 5 % of 
patients with HCM and is characterized by  systolic failure associated 
with left ventricular wall thinning and increased ventricular volume 12 .
Diastolic Dysfunction in HCM
Most of HCM patients have abnormalities in relaxation and 
filling.In diastole ,isovolumic relaxation stage is considerably 
lengthened and it causes a reduced rate and volume of filling. The 
contribution of atrial systole to ventricular filling is considerably 
increased13.
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Laboratory studies
Electrocardiogram
In nearly every individual with HCM there are 
electrocardiographic abnormalities seen. left ventricular hypertrophy 
can be assessed by voltage criteria and Left atrial enlargement can be 
seen. ST-T changes are present. Q waves which are pathological can be 
seen. 
Wolff-Parkinson-White pattern or syndrome can be detected in 
electrocardiogram by the presence of delta wave.Genetic Mutations 
encoding AMP-activated protein kinase (PRKAG2) and lysosome 
associated membrane protein 2 are associated with WPW syndrome .
24 hour Holter monitoring  and treadmill stress testing can be 
used for finding out arrhythmias and stratification of risk . Nonsustained 
ventricular tachycardia detected by 24 hrs Holter monitoring and a
blood pressure response which is abnormal to treadmill testing are risk 
factors for sudden death7.
Echocardiographic evaluation of HCM
      For the diagnosis of hypertrophic cardiomyopathy echocardiography 
is a very important tool. The diagnosis can be established by
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echocardiography,it is also very useful for followup and stratification of 
risk for sudden death. Probable or definite echocardiographic evidence 
of HCM is detected on the basis of recognition of a hypertrophied left 
ventricle with inter ventricular septum /posterior wall thickness ≥1.3 
.When the right ventricular wall thickness exceeds 4 mm the right 
ventricle is considered to be involved too . Asymmetric left ventricular 
hypertrophy is the hallmark of HCM, the hypertrophy is more marked in
the interventricular septum .Concentric hypertrophy has also been seen 
in some individuals.  Apical hypertrophy and isolated hypertrophy of 
anterior wall or the mid part of left ventricle can also be seen. The mid 
ventricular obstruction may lead to the development of an apical left 
ventricular aneurysm.Left atrial enlargement can be seen due to result of 
mitral regurgitation and diastolic dysfunction. Systolic anterior motion
of anterior mitral leaflet found in patients with hypertrophic obstructive 
cardiomyopathy is seen . Color flow Doppler allows to find the location
of obstruction. Continuous wave Doppler can be used to find the left 
ventricular outflow tract gradient . The severity of Mitral regurgitation 
can be found out by continuous wave doppler.  The primary mitral valve 
abnormalities are better detected by Transesophageal echocardiography 
.The primary mitral valve abnormalities can cause mitral regurgitation 
in patients with HCM.
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When there is no resting gradient ,exercise Stress echo can be 
used to bring out the latent gradient in HCM . Doppler flow velocities 
across miral inflow and pulmonary vein can be used to find out diastolic 
dysfunction in hypertrophic cardiomyopathy .
For the detection of diastolic dysfunction in HCM ,tissue Doppler 
is very useful and more sensitive than pulse doppler .Using tissue 
Doppler we can detect HCM in carriers of the genetic mutation even
before the development of hypertrophy 
For identification of hypertrophic cardiomyopathy carriers 
reduced systolic and diastolic tissue doppler velocities have a high 
sensitivity and specificity 
The prominent diastolic abnormality seen in patients with HCM is 
impaired LV relaxation  . For the detection of high filling pressures, 
Mitral inflow and pulmonary venous flow assessments are not  
sensitive. LV filling pressure, peak E velocity of mitral inflow and 
mitral annular velocities (Ea) detected by tissue doppler have a good 
correlation.The realaxation abnormalities can be detected even before 
the start of hypertrophy in individuals with HCM . The response to 
septal ablation and surgery can be monitored by tissue doppler
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Computed tomography and Cardiac MRI :
CT and Cardiac MRI are very useful when thoracic deformities 
prevent satisfactory cardiac visualization by transthoracic 
echocardiography. Cardiac MRI has also demonstrated that mitral 
leaflet elongation is present in hypertrophic cardiomyopathy 
independently of other phenotypic variants indicating that the mitral 
abnormalities are primary, thus, their important role in the 
pathophysiology of the obstruction in LVOT . 
Gadolinium magnetic resonance imaging late enhancement 
allows detection of the amount of myocardial fibrosis and is a predictor 
of systolic dysfunction
Cardiac catheterization :
Cardiac catheterization  helped in the initial understanding of the 
physiopathology of hypertrophic cardiomyopathy .Noninvasive imaging  
techniques like Doppler-echocardiography, computed tomography, and 
magnetic resonance imaging have replaced cardiac catheterization for 
diagnostic purposes. Nowadays, this method is only used before planned 
surgical treatment or percutaneous interventions for septal reduction.
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Complications of HCM :
Main complications in children with HCM are syncope and sudden  
death. Sudden cardiac death may be initial presentation of the disease 
and is considered to be secondary to ventricular tachycardia and 
fibrillation caused by myocardial fibrosis and ischemia . Sudden death 
occurs more often in older children with hypertrophic cardiomyopathy 
either during strenuous sport activities or at rest but is infrequent in 
infants  who are more prone to present and die with congestive heart 
failure specially in secondary forms .
Arrhythmias: Supraventricular and nonsustained ventricular 
tachycardias, were found in almost a third of pediatric and adolescent 
patients with hypertrophic cardiomyopathy studied by ambulatory 
electrocardiography  Rarely, 3rd degree atrioventricular block is found 
in children with hypertrophic cardiomyopathy. They could present with 
near syncope or syncopal attacks as the first manifestation of the disease 
Nonsustained ventricular tachycardia:
Most of the patients in this age group do not have nonsustained 
ventricular tachycardia in holter monitoring.Nonsustained ventricular 
tachycardia can be seen during 24 hrs holter monitoring in 20% to 30% 
of adults14.  
16
Evolving phenotype
Children with hypertrophic cardiomyopathy may evolve to dilated 
or restrictive cardiomyopathy phenotypes in 5% of the cases. In both 
circumstances they have a poor prognosis and become candidates for 
heart transplantation .
Infectious endocarditis
Infectious endocarditis is a rare  complication in hypertrophic 
cardiomyopathy Infectious endocarditis can affect the  anterior mitral 
valve leaflet in the ventricular side.
Stroke
Ischemic stroke is somewhat frequent and a cause of death in 
adult hypertrophic cardiomyopathy but has not been seen in children .
Medical treatment in HCM:
Beta-blockers and verapamil  are used on an empirical basis. 
Most physicians  use beta-blockers as the firstline drug in the treatment 
of HCM.Verapamil is not preferred as the initial drug. 
Beta-blockers or verapamil do not have evidence for prevention 
of sudden cardiac death.
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Symptom relief can be seen in most of patients who are on beta-
blockers or verapamil.Medical therapy is used for only symptomatic 
patients.Medical therapy cannot be used prophylactically.
Surgery  in HCM :
Surgical indication for patients with HCM are a very high 
gradient, severe symptoms and failure of drug treatment .Myectomy has 
become the primary option for these patients.five to ten grams of muscle 
are resected from tha basal septum by surgery. 
The LVOT gradient is reduced  in more than 90% of patients and 
provides symptomatic improvement in functional status15.
DDD pacing to relieve LVOT obstruction
DDD pacing with shortened A-V delay was used to reduce the 
outflow gradient and improve quality of life in patients with HCM  who 
are failures of medical treatment. The mechanism of action causing this 
lowering of left ventricular outflow gradient is not known. Several trials 
have found out that DDD pacing is not effective in the treatment of 
HCM16.They have suggested only a placebo role in the symptomatic 
improvement seen in patients who have been treated with DDD pacing. 
Now DDD pacing is not recommended for treatment of patients with 
obstructive HCM.
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Alcohol septal ablation :
The first septal artery when temporarily occluded by an 
angioplasty balloon caused a reduction in LVOT gradient. This formed 
the basis for alcohol septal ablation as a treatment option for 
HCM17.Contrast echocardiography is utilised for assessing the perfusion 
bed supplied by first septal artery and it is marked out and it  predicts  
the infarct size following alcohol injection.
RISK STRATIFICATION  IN HCM
Hypertrophic cardiomyopathy is the most frequent etiology of 
sudden cardiac death  in young . Male preponderance is seen among 
athletes . 
The primary prevention risk factors for SCD in HCM include 
family history of SCD, unexplained recent syncope, runs of 
nonsustained ventricular tachycardia on 24 hrs Holter monitoring, 
hypotensive response to exercise and maximum left ventricular wall 
thickness greater than 30 mm18 .
Sustained ventricular tachycardia and ventricular fibrillation are 
the most important causes of SCD . Increased SCD risk is caused due to 
excess sympathetic activation during exercise. 
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SUDDEN CARDIAC DEATH PREVENTIVE MEASURES IN 
HCM
Betablockers and verapamil do not prevent sudden cardiac death 
in hypertrophic cardiomyopathy 
Implantation of  ICD is the most effective procedure to prevent 
sudden cardiac death in HCM. ICD is primarily used for secondary 
prevention and in primary prevention of sudden cardiac death in HCM 
and this has been proved in many studies19. 
ICD implantation in HCM is a class I indication for secondary 
prevention and classIIB for primary prevention as given in guidelines of 
AHA/ACC/NASPE 20.
The disadvantage of ICD is its high cost.History of prior cardiac
arrest or spontaneous sustained ventricular tachycardia in patients is a 
mandatory indication for ICD implantation.
For primary prevention of sudden cardiac death in children, ICD 
implantation is not preferred.Amiodarone can be used as bridge to ICD 
implantation in children till they reach adulthood.
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MATERIALS AND METHODS
This was a retrospective cross-sectional study done between 
March 2012 and March 2013 at the department of cardiology, 
Government General Hospital Chennai. The study cohort comprises 40  
patients with Hypertrophic cardiomyopathy who are referred to the
department of cardiology, for evaluation or follow up.
SETTING : Department of Cardiology, Rajiv Gandhi 
Government General,                                                                   
Madras Medical College, Chennai.
 DESIGN OF STUDY     : PProspective observational study
 PERIOD OF STUDY     :  1 Year
 SAMPLE SIZE               :  40 
INCLUSION CRITERIA
• Probable or definite echocardiographic evidence of HCM 
on the basis of recognition of a hypertrophied  left ventricle with inter 
ventricular septum /posterior wall thickness ≥1.3 
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EXCLUSION CRITERIA
1) Non-diagnostic echocardiographic studies
2) Other concomitant loading or systemic conditions that may lead 
to  left ventricular hypertrophy -Systemic hypertension ,Aortic
stenosis,Coarctation, or Structural LVOT obstruction
3) HCM patients who have undergone  surgical or catheter septal 
myectomy
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STUDY PROCEDURE
All patients referred for echocardiography during this period were 
included. 
1) 2D, M-mode,Pulseand Tissue  Doppler measurements taken.
2) Diastolic function of both Left ventricle and Right ventricle 
evaluated.       
3) Detecting and grading of the systolic anterior motion of the mitral 
valve, LV outflow tract obstruction, intracavitary obstruction and 
mitral regurgitation assessed.
4) Describing the pattern of left ventricular hypertrophy
DATA COLLECTION and ANALYSIS
• Interviewer will administer the proforma. Past medical 
history and relevant history will be collected as per hospital record after 
explaining aim of the study  & getting written consent
• Demographic data such as age, gender, and clinical 
presentation; ECG data and echocardiographic data will be  described 
and analysed.
• Echocardiography done on Philips HD7XE machine .
• 24 hour HOLTER study  done for  patients. 
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ECHOCARDIOGRAPHIC EVALUATION OF 
BIVENTRICULAR DIASTOLIC FUNCTION IN HCM
Transthoracic Echocardiography was performed in all 
hypertrophic cardiomyopathy patients with Philips HD7XE machine  . 
Interventricular septum thickness, left ventricular posterior wall 
thickness, left ventricular end diastolic diameter, left ventricular end 
systolic diameter, right ventricular free wall thickness, right ventricular 
end diastolic diameter,   fractional shortening of left ventricle were the 
variables assessed .
The left ventricular diastolic function was determined from the 
transmitral pulse doppler inflow patterns taken from the apical four-
chamber view by positioning sample volume at the tips of the mitral 
leaflets during diastole.
Right  ventricular diastolic function was assessed from the apical 
4 chamber view  by sample volume at the tips of tricuspid leaflets 
during diastole. 
peak velocity of E wave of tricuspid inflow , peak velocity of A 
wave of tricuspid inflow, E/A ratio, deceleration time of E wave and
right ventricular isovolumic relaxation time were calculated for 
assessment of right ventricular diastolic function. 
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TISSUE DOPPLER IMAGING
The tissue doppler velocity of myocardium was measured at 
septal side of mitral valve annulus to determine Septal mitral annular 
tissue Doppler velocity MV Ea and MV Aa . The tissue doppler velocity 
of myocardium was measured at lateral side of tricuspid valve annulus 
to determine lateral tricuspid annular tissue Doppler velocity TV Ea and 
TVAa. In our study the  patients were divided into two groups according 
to their left ventricular outflow gradient gradient less than 30 mmHg 
were the non-obstructive HCM group, and LV outflow gradient more 
than 30 mmhg were the obstructive HCM group.
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CLASSIFICATION OF HCM PATIENTS ACCORDING TO 
MARON SUBTYPES21
Type I : Hypertrophy confined to the anterior portion of the ventricular 
septum. 
Type II : Hypertrophy involving the anterior and posterior septum
Type III : Hypertrophy involving the anterior and posterior septum as 
well as the lateral free wall. 
Type IV :Hypertrophy involving left ventricular regions other than the 
anterior septum and the posterior free wall
• using short-axis view the left ventricle is divided in 4 LV wall 
segments: anterior and posterior septum and posterior and lateral 
wall Segments are visualized at mitral and papillary level.
• possible extension to the apex is visualized by 4 chamber view
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Statistical Analysis
All the obtained data were analyzed by Medcalc 
software.Continuous data are expressed as mean values ± SD.Student’s 
t-test was used to assess the significant differences of mean values 
between patients with non-obstructive and obstructive HCM. A p-value 
≤0.05 was considered statistically significant.
Pearson correlation coefficient was used to assess the correlation 
between right Ventricle and left ventricle diastolic parameters.
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RESULTS
TABLE 1 : BASELINE CHARACTERISTICS OF STUDY-( n = 40) 
PATIENTS
MALE/FEMALE 31/9
AGE 41.8 ±10.7
SYMPTOMS
          BOE 18 (45%)
          PALPITATION 22 ( 55%)
          ANGINA 22 ( 55%)
          SYNCOPE 21 (52.5%)
FAMILY H/O SCD 11 (27.5%)
HOLTER-NSVT 10 (25%)
MARON 
CLASSIFICATION
            TYPE I 3 (7.5%)
             TYPE II 6 (15%)
             TYPE III 15 (37.5%)
             TYPE 1V 16 (40 %)
             TYPE V 0
LVEDD (mm) 42.1± 4.4
LVESD (mm) 24.1 ±3.8
FS   (%) 41.7± 7.9
OBSTRUCTIVE HCM-
LVOTG > 30 mm Hg
13 ( 32.5%)
SAM
         GRADE 1 4 (10%)
         GRADE II 6 (15%)
          GRADE III 3 (7.5%)
          GRADE IV 0
MITRAL 
REGURGITATION
         GRADE 1 5 (12.5%)
         GRADE II 8 (20%)
          GRADE III 0
          GRADE IV 0
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The study cohort comprises 40 consecutive patients with 
Hypertrophic cardiomyopathy who were referred to our department for 
evaluation or follow up. There were 31 male and 9 female patients in 
our study.
Mean age (± SD) was 41.8 years (± 10.7), for males 43.3 (± 9.6) 
yrs, and for females 36.7 (± 13.5) yrs.
TABLE 2 :  AGE DISTRIBUTION
AGE N = 40 ( % )
20-29 4 ( 10 %)
30-39 13 ( 32.5 % )
40-49 12 (30 %)
50-59 8 ( 20 %)
60-69 3 ( 7.5 %)
TOTAL 40
10 % of patients were in  20-29 years age group.32.5 % of 
patients were in 30-39 years age group.30% of patients were in 40-49 
years age group.20% of patients were in 50-59 years age group.7.5% of 
patients were in 60-69 years age group
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FIGURE 1
TABLE 3: AGE DISTRIBUTION ACCORDING TO MARON TYPES
TYPE NO (%) AGE (YRS)
I 3 ( 7.5 %) 49 ± 6.5
II 6 (15%) 38 ± 8.8
III 15 (37.5 %) 42.1± 11.2
IV 16 ( 40 % ) 41.6 ±11
TOTAL 40 41.8 ± 10.7
Mean age (± SD) of Maron type I patients were 49 ± 6.5 years. 
Mean age (± SD) of Maron type II patients were 38 ± 8.8 years. Mean 
age (± SD) of Maron type III patients were 42.1± 11.2 years. Mean age 
(± SD) of Maron type IV patients were 41.6 ± 11.2 years .
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TABLE 4: FREQUENCY ACCORDING TO TYPES IN 
MARONS CLASSIFICATION
TYPE N0 (%)
I 3 ( 7.5 %)
II 6 (15%)
III 15 (37.5 %)
IV 16 ( 40 % )
V Nil
TOTAL 40
The patients were categorized according to the Maron types of 
HCM. 7.5 % of patients were in type I.15 % of patients were in type II. 
40 % of patients were in type IV  and 37.5% patients were in type III 
Maron . There were no patients with type V (apical HCM) Maron.
FIGURE 2 :N0 OF PTS ACCORDING TO MARON TYPES
TABLE 5 : CATEGORIZATION OF OBSTRUCTIVE HCM 
ACCORDING TO MARON TYPES   
TYPE
1
II
111
1V
TOTAL
Left ventricular obstruction
No obstruction was found in 27 (67.5%) patients. 32.5 % of 
patients had obstructive HCM (>30 mmHg  LV outflow obstruction) 
was found in 13 (32.5 %) cases,with a rest gradient mean(+SD) of 65 (
31.5) mmHg.
16( 40%)
31
NO (%) NO OF 
OBSTRUCTIVE TYPE
3 ( 7.5 %) 0
6 (15%) 0
15 (37.5 %) 7 (46.7%)
16 ( 40 % ) 6 (40%)
40 ( 100%) 13 (32.5%)
3(7%)
6(15%)
15( 38%)
TYPE I
TYPE II
TYPE III
TYPE 1V
± 
32
46.7 % of Maron type III HCM patients had obstructive HCM 
and 40%  of Maron type IV HCM patients had obstructive HCM 
FIGURE 3:CATEGORIZATION OF OBSTRUCTIVE AND 
NONOBSTRUCTIVE HCM BY MARON TYPES 
TABLE 6 FREQUENCY OF SAM  ACCORDING TO THE 
TYPES IN MARON”S CLASSIFICATION
TYPE NO (%) NO OF SAM (%)
1 3 ( 7.5 %) 0
II 6 (15%) 2 (33.3%)
111 15 (37.5 %) 10(66.7%)
1V 16 ( 40 % ) 9 (56.25%)
TOTAL 40 ( 100%) 21 ( 52.5%)
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FIGURE 4:
No patients in Maron Type I HCM had Systolic anterior motion 
of mitral leaflet (SAM).66.7 % OF Type III and 56.25 % of type IV 
HCM had SAM.
TABLE 7 : SEPTUM AND LVPW THICKNESS ACCORDING 
TO MARON TYPES 
TYPE SEPTUM (mm) LVPW(mm)
I 20.1  ± 2.1 9.1 ± 0.9
II 18.6 ± 2.4 9.5 ± 0.5
III 15.9 ± 2.9 8.5 ± 1.3
IV 16.9 ± 2.8 9.2 ± 1.8
TOTAL 17.3 ± 2.3 8.9± 1.4
FIGURE 5:COMPARISION OF SEPTAL THICKNESS 
ACCORDING TO MARON TYPES OF HCM
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FIGURE 6:
MARON TYPES OF HCM
Type I
Type II
Type III
Type IV
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The maximum septal thickness was 21.8 mm. The mean septal 
thickness and (±SD) was 17.3 (±2.3) mm.
The maximum LV posterior wall dimension was 12 mm. The 
mean LV posterior wall thickness(±SD) was 8.9 (±1.4) mm
The mean septal thickness and (±SD) of Maron type I was 20.1 (± 
2.1) mm. The mean septal thickness and (±SD) of Maron type II was 
18.6 (± 2.4) mm. The mean septal thickness and (±SD) of Maron type 
III was 15.9 ( ± 2.9) mm. The mean septal thickness and (±SD) of 
Maron type IV was 16.9 (± 2.8) mm.
TABLE 8 :CATEGORIZATION OF MITRAL INFLOW 
VELOCITIES ACCORDING TO MARON TYPES
TYPE LV-PV E (cm/s) LV-PVA(cm/s) LV-DTE (msec)
I 53.2 ± 8.2 53.2± 17.2 256± 14.7
II 79.1± 16.5 58.8 ± 11.3 162.3 ± 45
III 74.5± 24.8 82.4 ± 34.9 186.6±47.7
IV 107.2±42.5 69 ± 17.6 155 ± 31.9
TOTAL 86.6±35.3 71.3 ± 26 175.5 ±  46.6
The mean (± SD) of peak velocity E of mitral inflow velocity of 
all patients is 86.6±35.3 cm/s.The mean (± SD) of peak velocity A of 
mitral inflow velocity of all patients is 71.3 ± 26 cm/s.
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The mean (± SD) of peak velocity E of mitral inflow velocity of 
type I Maron HCM patients is 53.2 ± 8.2 cm/s  . The mean (± SD) of 
peak velocity A of mitral inflow velocity of type I Maron HCM patients 
is 53.2± 17.2 cm/s.
The mean (± SD) of peak velocity E of mitral inflow velocity of 
type II Maron HCM patients is 79.1± 16.5 cm/s. The mean (± SD) of 
peak velocity A of mitral inflow velocity of type II Maron HCM 
patients is 58.8 ± 11.3 cm/s
The mean (± SD) of peak velocity E of mitral inflow velocity of 
type III Maron HCM patients is 74.5± 24.8 cm/s. The mean (± SD) of 
peak velocity A of mitral inflow velocity of type III Maron HCM 
patients is 82.4 ± 34.9 cm/s.
The mean (± SD) of peak velocity E of mitral inflow velocity of 
type IV Maron HCM patients is107.2±42.5 cm/s. The mean (± SD) of 
peak velocity A of mitral inflow velocity of type IV Maron HCM 
patients is 69 ± 17.6 cm/s.
The mean (± SD) of deceleration time of mitral inflow E velocity 
in all patients is 175.5 ±  46.6 msec.
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The mean (± SD) of deceleration time of mitral inflow E velocity 
in type I Maron is 256± 14.7 msec. The mean (± SD) of deceleration 
time of mitral inflow E velocity in type II Maron is 162.3 ± 45 msec. 
The mean (± SD) of deceleration time of mitral inflow E velocity in 
type III Maron is 186.6±47.7 msec. The mean (± SD) of deceleration 
time of mitral inflow E velocity in type IV Maron is 155 ± 31.9 msec.
TABLE 9 :CATEGORIZATION OF TRICUSPID INFLOW 
VELOCITIES ACCORDING TO MARON TYPES
TYPE RV-PV E(cm/s) RV-PV A(cm/s) RV-DTE (msec)
I 41.8 ±1 42.3 ± 6.9 161.7 ± 55.5
II 56.9 ±12.7 43.7 ±7.1 203 ± 63.4
III 50 ± 11.7 46.2 ± 10.6 221.8 ± 60.4
IV 60.4± 13.6 46.7 ±22.7 193.6 ±60.4
TOTAL 54.6 ±13.1 45.7± 15.6 203.3± 60.6
FIGURE 7
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The mean (± SD) of peak velocity E of tricuspid inflow velocity 
of all patients is 54.6±13.1 cm/s.The mean (± SD) of peak velocity A of 
tricuspid inflow velocity of all patients is 45.7 ± 15.6 cm/s.
The mean (± SD) of peak velocity E of tricuspid inflow velocity 
of type I Maron HCM patients is 41.8 ± 1 cm/s  . The mean (± SD) of 
peak velocity A of tricuspid inflow velocity of type I Maron HCM 
patients is 42.3± 6.9 cm/s.
The mean (± SD) of peak velocity E of tricuspid inflow velocity 
of type II Maron HCM patients is 56.9± 12.7 cm/s. The mean (± SD) of 
peak velocity A of tricuspid inflow velocity of type II Maron HCM 
patients is 43.7± 7.1 cm/s
The mean (± SD) of peak velocity E of tricuspid inflow velocity 
of type III Maron HCM patients is 50± 11.7 cm/s. The mean (± SD) of 
peak velocity A of tricuspid inflow velocity of type III Maron HCM 
patients is 46.2 ± 10.6 cm/s.
The mean (± SD) of peak velocity E of tricuspid inflow velocity 
of type IV Maron HCM patients is 60.4± 13.6 cm/s. The mean (± SD) of 
peak velocity A of tricuspid inflow velocity of type IV Maron HCM 
patients is 46.7 ± 22.7 cm/s.
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The mean (± SD) of deceleration time of tricuspid inflow E 
velocity in all patients is 203.3± 60.6 msec.
The mean (± SD) of deceleration time of tricuspid inflow E 
velocity in type I Maron is 161.7 ± 55.5 msec. The mean (± SD) of 
deceleration time of tricuspid inflow E velocity in type II Maron is 203 
± 63.4msec. The mean (± SD) of deceleration time of tricuspid inflow E 
velocity in type III Maron is 221.8 ± 60.4msec. The mean (± SD) of 
deceleration time of tricuspid inflow E velocity in type IV Maron is 
193.6 ±60.4 msec.
FIGURE 8
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TABLE 10 : CHARACTERISTICS OF MITRAL INFLOW 
VELOCITIES BETWEEN NON-OBSTRUCTIVE AND 
OBSTRUCTIVE HCM
NON-
OBSTRUCTIVE 
(n=27)
OBSTRUCTIVE
(n = 13)
P value
LV-PVE 83.6  ± 32.5 93 ± 39.9 0.43
LV-PV A 71.9 ± 28.5 70 ± 19.6 0.82
LV-DTE 179.6±48.9 167.1 ±40 0.42
LVOT 
GRADIENT
6.8 ± 4.2 65± 31.5 <0.0001
FIGURE 9  CHARACTERISTICS OF MITRAL INFLOW 
VELOCITIES BETWEEN NON-OBSTRUCTIVE AND 
OBSTRUCTIVE HCM
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The mean (± SD) of peak velocity E of mitral inflow velocity of  
patients with non-obstructive HCM is 83.6  ± 32.5 cm/s.The mean (± 
SD) of peak velocity A of mitral inflow velocity of  patients with non-
obstructive HCM is 71.9 ± 28.5 cm/s. The mean (± SD) of deceleration 
time of mitral inflow E velocity in non-obstructive HCM is 179.6±48.9 
msec.
The mean (± SD) of peak velocity E of mitral inflow velocity of  
patients with obstructive HCM is 93 ± 39.9 cm/s.The mean (± SD) of 
peak velocity A of mitral inflow velocity of  patients with obstructive 
HCM is 70 ± 19.6 cm/s. The mean (± SD) of deceleration time of mitral 
inflow E velocity in patients with obstructive HCM is 167.1 ±40 msec.
There was no significant statistical difference in mitral and tricuspid 
inflow velocities between non-obstructive and obstructive HCM.
TABLE   11.  Tissue Doppler Imaging velocities in patients with 
Hypertrophic cardiomyopathy
Patients ( n = 40) cm/s
MV Ea (septal) 5.8 ±2.4
MV Aa (septal) 6.5 ± 1.8
TV Ea (lateral) 13.4 ± 7.9
TV Aa (lateral) 18.8 ± 10.1
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TABLE 12      Comparison the results of Tissue doppler velocities 
according to left ventricle outflow gradient
NON-
OBSTRUCTIVE
(n=27)
OBSTRUCTIVE
(n=13)
p-value
MV Ea (septal) 5.7± 2.3 5.8 ±2.7 0.9
MV Aa (septal) 6.6± 1.9 6.5± 1.8 0.87
TV Ea (lateral) 13.3± 7.6 13.5± 8.4 0.94
TV Aa (lateral) 17.8± 9.6 20.9± 10.7 0.36
FIGURE 10 : Comparison the results of Tissue doppler velocities 
according to left ventricle outflow gradient
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All myocardial tissue Doppler velocities are decreased in the 
patients with HCM in comparison to the normal values.
Septal mitral annular tissue Doppler velocity MV Ea (septal)   has 
a mean of 5.8 cm/s (±SD 2.4). MV Aa (septal) has a mean of 6.5  cm/s 
(± SD 1.8).  Tricuspid annular tissue Doppler velocity TV Ea (lateral) 
has a mean of 13.4 cm/s (± SD 7.9).TV Aa (lateral) has a mean of 18.8 
cm/s (± SD 10.1)
Septal mitral annular tissue Doppler velocity MV Ea (septal) in 
non-obstructive HCM  has a mean of 5.7 cm/s (±SD 2.3). MV Aa 
(septal) has a mean of 6.6  cm/s (± SD 1.9).  Tricuspid annular tissue 
Doppler velocity in non-obstructive HCM TV Ea (lateral) has a mean of 
13.5 cm/s (± SD 8.4).TV Aa (lateral) has a mean of 17.8 cm/s (± SD 
9.6).Septal mitral annular tissue Doppler velocity MV Ea (septal) in 
obstructive HCM  has a mean of 5.8 cm/s (±SD 2.7). MV Aa (septal) 
has a mean of 6.5  cm/s (± SD 1.8).  Tricuspid annular tissue Doppler 
velocity in obstructive HCM TV Ea (lateral) has a mean of 13.3 cm/s (± 
SD 7.6).TV Aa (lateral) has a mean of  20.9 cm/s (± SD 10.7)
There was no significant statistical difference in mitral and 
tricuspid tissue doppler velocities between non-obstructive and 
obstructive HCM.
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TABLE 13  CORRELATION BETWEEN RV AND LV 
DIASTOLIC PARAMETERS
LV-E/A LV-DTE
RV-E/A r = 0.36
p = 0.02
r = 0.34
p=0.03
RV-DTE r = -0.32
p=0.04
r = 0.1
p=0.5
Correlation between RV and LV diastolic parameters were tested 
using pearson Correlation coefficient.There is significant correlation 
between right ventricle E/A ratio and left ventricle E/A ratio and left 
ventricular deceleration time of E wave.  There is also significant 
correlation between right ventricle deceleration time of E wave and left 
ventricle E/A ratio.
FIGURE 11        
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FIGURE 12:
There was no significant correlation between right ventricle 
deceleration time of E wave and left ventricle deceleration time of E 
wave.There was no significant correlation between tissue Doppler 
velocities of right ventricle and left ventricle.There was no significant 
correlation between right ventricle pulse and tissue Doppler parameters 
and septal wall thickness,right ventricle free wall thickness
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TABLE  14: CLINICAL MANIFESTATIONS ACCORDING TO 
TYPES IN MARONS CLASSIFICATION
TYPE No. SYMPTOMS BOE PALPITATION SYNCOPE CHESTPAIN
I 3
(7.5 
%)
2 (66.7%) 1(33.3%) 2 (66.7%)
II 6
(15%)
5 (83.3%) 2 
(33.3%)
3 (50%) 4 ( 66.7%)
III 15
(37.5 
%)
15 (100%) 7 
(46.7%)
10 (66.7%) 6 (40%) 12 (80%)
IV 16 
( 40 
% )
16 (100%) 9 
(56.25%)
8 (50%) 9 (56.25%) 10 (62.5%)
TOTAL 40 37 (92.5%) 18 (45%) 22(55%) 21(52.5%) 22(55%)
92.5 % of patients with HCM had symptoms . chest pain and 
palpitation were present in 55 % of patients.Syncope was seen in 52.5% 
of patients. 45% of patients had breathlessness on exertion ( BOE).66.7 
% of patients with Maron Type I HCM had symptoms of which 66.7 % 
had syncope and 33.3 %  of patients had palpitation.83.3 % of patients 
with Maron Type II HCM had symptoms of which 66.7 % had syncope , 
50 %  of patients had palpitation and 33.3% had breathlessness on 
exertion (BOE).All the patients with Maron Type III HCM had 
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symptoms of which 66.7 % had palpitation, 80 % of patients had chest 
pain,40 %  of patients had syncope and 46.7 % had breathlessness on 
exertion (BOE).All the patients with Maron Type IV HCM had 
symptoms of which 50 % had palpitation, 62.5% of patients had chest 
pain,56.25 %  of patients had syncope and  breathlessness on exertion 
(BOE).
TABLE 15:RISK STRATIFICATION OF HCM ACCORDING TO 
MARON TYPES
TYPE FAMILY 
H/O SCD
LV WALL 
THICKNESS 
> 30 mm
SYNCOPE HOLTER 
–NSVT
I 3 ( 7.5 
%)
0 0 2 (66.7%) 0
II 6 (15%) 4 (66.7%) 0 4 ( 66.7%) 0
III 15 
(37.5 
%)
3 (20%) 0 6 (40%) 4(26.7%)
IV 16 ( 40 
% )
4 (25%) 0 9 (56.25%) 6(37.5%)
TOTAL 40 11(27.5%) 0 21(52.5%) 10 (25%)
Family H/O sudden cardiac death was present in 27.5% of 
patients with HCM.66.7% of patients with Maron Type II had a family 
history of sudden cardiac death.20% of patients with Maron Type III 
had a family history of sudden cardiac death and 25 % of patients with 
Maron Type II had a family history of sudden cardiac death.
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No patient had a maximum LV wall thickness of greater than 30 
mm. Non-sustained ventricular tachycardia as detected by 24hrs Holter 
study was present in 25% of patients with HCM. Non-sustained 
ventricular tachycardia as detected by 24hrs Holter study was present in 
26.7% of type III Maron HCM patients.. Non-sustained ventricular 
tachycardia as detected by 24hrs Holter study was present in 37.5 % of 
type IV Maron HCM patients.
Syncope was seen in 52.5% of all patients with HCM. Syncope 
was seen in 66.7% of patients with Maron Type I and II. Syncope was 
seen in 40 % of patients with Maron Type III and 56.25% patients with 
Maron type IV.
FIGURE 13
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DISCUSSION
The prevalence of HCM in the adult general population is about 
0.2% (1:500) based on several epidemiological studies21,22. Many 
patients having the mutant gene for HCM can go undetected clinically. 
Our study patients were those referred for echocardiography to our 
cardiology OPD.Our study is not a community screening study 
.Therefore one would expect it to underestimate the phenotypic 
prevalence in the community. The population harbouring the genetic 
defect is also underestimated.
Similar prevalence of HCM was found in no more than 1% of 
outpatients in Other studies which had patients as referrals to hospital22.
The prevalence in females was significantly less than expected. 
Male prevalence ranged from 55% to 78% in previous studies23,24.
There were 31 male and 9 female patients in our study.The 
female population is significantly lower in our study.only 22.5% of the 
study patients were female.
Reduced patient awareness,26,lesser indications for medical 
screening programs25,27, and referral bias of clinicians26 or  clinical 
presentation which is delayed, which can result from genetic and 
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endocrine factors  affecting expression of phenotype of the disease. 
Estrogens may have a protective effect on development of secondary 
hypertrophy28,29 .
The nature of the study population  was predominantly male in 
our study.
32.5 %  of patients were in the 30-39 years age group and 30% 
were in the 40-49  years age group.Hence majority of patients studied in 
our study were in the 30-49 years age group.
our population were younger (mean age 41.8 ± 10.7 yrs) and it is 
to be noted that male predominance were seen from adolescence to mid-
life in different studies.
Presence of LVOT obstruction in HCM
For categorization of HCM patients into different groups various 
cutoff based on LV outlow gradient and site of hypertrophy have been 
used. Strict categorization into different categories according to  LV 
outflow gradient is difficult because of the unpredictability of dynamic 
changes that may occur in different patients. In our study we used 30 
mmHg as a rest cut-off and /or a 50 mmnHg as a provocative induced  
LV outflow gradient. No obstruction was found in twenty seven (67.5%) 
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patients. Thirteen (32.5 %) of patients had obstructive HCM (>30 
mmHg  LV outflow obstruction) was found in 13 (32.5 %) cases,with a 
rest gradient mean(+SD) of 65 (± 31.5) mmHg.
46.7 % of Maron type III HCM patients had obstructive HCM 
and 40%  of Maron type IV HCM patients had obstructive HCM .There 
was no obstructive HCM in Maron type I and II.
LV outflow obstruction prevalence have been from 23 – 77% in 
different studies30-32. Patients with obstructive HCM were older than 
other groups. Many of our patients where on medical therapy which 
may account for the low gradient in them. 
LV hypertrophy patterns :
The classification of the left ventricular hypertrophy pattern in 
HCM has not been universally formalised. The most commonly used is 
the Maron classification21.
The patients in our study were categorized according to the 
Maron types of HCM.
7.5 % of patients were in type I.15 % of patients were in type II. 
40 % of patients were in type IV  and 37.5% patients were in type III 
Maron .
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There were no patients with type V (apical HCM) Maron.Type IV 
Maron was the predominant group in our study,which is in contrast to 
other studies were type III Maron was the predominant group21.
The four patterns of  Maron types of LV hypertrophy showed no 
difference in age. 92.5 % of patients with HCM had symptoms . chest 
pain and palpitation were present in 55 % of patients.Syncope was seen 
in 52.5% of patients. 45% of patients had breathlessness on exertion ( 
BOE).
66.7 % of patients with Maron Type I HCM had symptoms of 
which 66.7 % had syncope and 33.3 %  of patients had palpitation.83.3 
% of patients with Maron Type II HCM had symptoms of which 66.7 % 
had syncope , 50 %  of patients had palpitation and 33.3% had 
breathlessness on exertion (BOE).
All the patients with Maron Type III HCM had symptoms of 
which 66.7 % had palpitation, 80 % of patients had chest pain,40 %  of 
patients had syncope and 46.7 % had breathlessness on exertion (BOE).
All the patients with Maron Type IV HCM had symptoms of 
which 50 % had palpitation, 62.5% of patients had chest pain,56.25 %  
of patients had syncope and  breathlessness on exertion (BOE).
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Syncope was present in all groups.The prevalence of syncope was 
higher in Maron type I and II.Majority of patients had chestpain in type 
III and IV. Chest pain as a symptom was not seen in type I and II.
Biventricular diastolic dysfunction in HCM
As shown in table 8 & 9, all myocardial velocities decreased in 
the patients with HCM in comparison to the normal values. Recent 
studies have shown that tissue doppler is a reliable method for early 
detection of HCM in genotype-positive patients before the onset of 
hypertrophy. Reduction in systolic and diastolic Tissue doppler 
velocities have been shown in various studies to have a high sensitivity 
and specificity for identifying mutation in HCM carriers.
Serial echocardiographic evaluation of patients with clinically 
normal phenotype but carrying the mutation of HCM have shown  
reduction in tissue doppler velocities and development of hypertrophy 
and diastolic dysfunction during follow up after many years.Impaired 
LV relaxation is a prominent diastolic abnormality in patients with 
HCM. Mitral inflow and pulmonary venous pulse Doppler flow 
assessments may not be sensitive for the detection of high filling 
pressures of  the left ventricle. Simultaneous echocardiographic and 
invasive homodynamic studies have revealed no significant correlation 
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between mitral inflow or pulmonary venous flow parameters and filling 
pressures in patients with LV systolic dysfunction.Good correlation 
between LV filling pressure, mitral inflow E velocity, and tissue 
Doppler MV annular velocities (Ea) have been observed in studies. 
All myocardial tissue Doppler velocities are decreased in the 
patients with HCM in comparison to the normal values in our 
study.Reduced tissue doppler early diastolic velocities that have been 
detected in our study indicate that diastolic abnormalities may precede 
the onset of hypertrophy in HCM.
Patients in Type IV showed maximum peak velocity of  E  in  
mitral inflow velocities. Patients in Type III showed maximum peak 
velocity of   A  in  mitral inflow velocities.Deceleration time of Mitral 
inflow E  velocity was maximum in Maron Type I HCM 
patients.Patients in Type IV showed maximum peak velocity of   E and 
A  in  tricuspid inflow velocities. Deceleration time of tricuspid inflow 
E  velocity was maximum in Maron Type III HCM patients.There was 
no statistically significant relationship between myocardial tissue 
Doppler velocities of obstructive and non-obstructive HCM.This is in 
contrast to a study by Rezvaneh Salehi et al which has observed positive 
correlation between reduced mitral annular Ea septal tissue Doppler 
velocity  and LVOT gradient .
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In all our study patients right ventricular diastolic function is 
impaired, with prolonged isovolumic relaxation time, prolonged 
deceleration time of E wave  reversed E/A ratio and reduced tricuspid 
annular tissue Doppler velocities.
Different studies  using cardiac MRI have found out diastolic 
bnormalities of the right ventricle like reduced  rate of early filling and 
increased late filling in patients with HCM. 
The observations in our study indicate that both left and right 
ventricles exhibit similarities in abnormal diastolic filling patterns. Left 
ventricular and right ventricular diastolic abnormalities are not related to 
the magnitude and severity of left and right ventricular hypertrophy 
respectively in our study.
A  study by  Spirito et al has observed that abnormalities in left 
ventricular relaxation in hypertrophic cardiomyopathy patients is not 
related to the proportion and severity of left ventricular hypertrophy32.
The possible explanation for right ventricular diastolic 
dysfunction is Ventricular interdependence33.The ventricles even though 
are  separated are connected anatomically and functionally  in both 
series and parallel.
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The pulmonary circulation provides the serial connection hence 
loading conditions of one ventricle. common anatomical structures like 
interventricular septum,pericardium and muscle fibres maintain the 
parallel connection between the ventricles.This results in ventricular 
interdependence during systole and diastole. In our study there was a 
statistically significant correlation between several diastolic indexes of 
left ventricle and right ventricle. There is significant correlation between 
right ventricle E/A ratio and left ventricle E/A ratio and left ventricular 
deceleration time of E wave.  There is also significant correlation 
between right ventricle deceleration time of E wave and left ventricle 
E/A ratio Right ventricular hypertrophy  can be seen in more than 50% 
of patients with HCM33.
The disarray of myocardial fibres in hypertrophic cardiomyopathy 
is not limited to the left ventricle but also affects the right ventricle . 
Hence the right ventricular diastolic dysfunction observed in 
hypertrophic cardiomyopathy  in all our patients may be contributed by  
the disarray of myocardial fibres rather than  the severity of right 
ventricular hypertrophy.
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RISK STRATIFICATION OF HCM
Family H/O Sudden cardiac death
Family H/O sudden cardiac death was present in 27.5% of 
patients with HCM.This is in contrast to a study by Maron et al where 
10-20% had a family H/O sudden cardiac death and 5 % had more than 
two sudden cardiac deaths in the family which suggests a malignant 
form of HCM34.  66.7% of patients with Maron Type II had a family 
history of sudden cardiac death.20% of patients with Maron Type III 
had a family history of sudden cardiac death and 25 % of patients with 
Maron Type II had a family history of sudden cardiac death.
Maximum LV Wall thickness
No patient had a maximum LV wall thickness of greater than 30 
mm.This is in contrast to study by Maron et al where maximum LV wall 
thickness of greater than 30 mm was seen in < 3% of patients35.spirito et 
al and olivetto etal have found that maximum LV wall thickness of 
greater than 30 mm is a sudden cardiac death risk factor mainly in 
younger patients32.
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Non-sustained ventricular tachycardia 
Non-sustained ventricular tachycardia as detected by 24hrs Holter 
study was present in 25% of patients with HCM.This is similar to study 
by Monserrat et al where 19.6% of patients had NSVT36.They have 
concluded that sudden cardiac death is significantly increased in young 
patients with HCM  and NSVT. Non-sustained ventricular tachycardia 
as detected by 24hrs Holter study was present in 26.7% of type III 
Maron HCM patients.. Non-sustained ventricular tachycardia as 
detected by 24hrs Holter study was present in 37.5 % of type IV Maron 
HCM patients.
SYNCOPE
Syncope was seen in 52.5% of all patients with HCM. Syncope 
was seen in 66.7% of patients with Maron Type I and II. Syncope was 
seen in 40 % of patients with Maron Type III and 56.25% patients with 
Maron type IV.This is similar to a study by Maron et al where syncope 
was seen in greater than 50% of patients and where syncope was the 
only marker in  more than one third of patients35.
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                                 Study limitations
1. Our  study evaluated only the prevalence among patients referred 
for echocardiography and not among the community. 
2. Our study evaluated the patients during the time period of the 
study,rather than those who were first diagnosed. 
3. Provocative tests were not standardized and was not attempted in 
all patients. 
4. Many patients were on medications, which might alter the 
measured LV outflow gradient during the study or might have 
even abolished such a gradient in some and thus  the prevalence 
of the obstructive type of HCM may have been underestimated.
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CONCLUSION
1. Majority of patients were in Type III and Type IV of Maron 
classification of hypertrophic cardiomyopathy .
2. Syncope was the most common sudden cardiac death risk factor 
seen in our study.
3. Maximum LV wall thickness of greater than 30 mm , a sudden 
cardiac death risk factor was not present in our study.
4. There was no statistically significant relationship between 
myocardial tissue Doppler velocities of obstructive and non-
obstructive HCM.
5. There was no statistically significant relationship between pulse 
Doppler mitral inflow velocities of obstructive and non-
obstructive HCM.
6. Biventricular diastolic dysfunction is seen in most patients with 
HCM.
7. Right ventricular diastolic dysfunction may be contributed by the 
disarray of myocardial fibres rather than  the severity of right 
ventricular hypertrophy
8. There is a significant correlation between several right ventricular 
and left ventricular diastolic parameters
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Figure A : shows measurement of LVOT gradient in HCM
62
Figure B:shows Mitral inflow pulse wave Doppler tracing
Fig.C showing LVOT gradient with dagger-shaped appearance
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Figure.D showing measurement of RP interval
Fig.E showing categorization of HCM according to Maron types
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Fig.F showing TDI at tricuspid lateral annulus for assessment of RV 
diastolic function
Fig.G showing measurement of RT interval
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ACRONYMS & ABBREVIATIONS
HCM - Hypertrophic cardiomyopathy
LVEDP - Left Ventricular End Diastolic pressure
LVOT - Left Ventricular Outflow Tract
DDD - Dual Chamber Pacing
ICD - Implantable Cardioverter Defibrillator 
WPW - Wolf Parkinson White Syndrome
SAM - Systolic Anterior Motion
BOE - Breathlessness On Exertion
NSVT - Non Sustained Ventricular Tachycardia
S D - Standard deviation
ACC - American College of Cardiology
AHA - American Heart Association
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PROFORMA
Name :
Age : 
Sex : 
Address :  
CD No. :
SYMPTOMS :
No symptoms:
Chest pain:
SOB Class:
Palpitations
Syncope
Risk Factors
Hypertension                                            Diabetes Mellitus
                                        
Smoking                                                    Family History
                                                   
Menopause
Past History :
Treatment History
Physical Examination
1. General Examination
2. Vital Signs
B.P
73
Pulse
Respiration JVP Height  cm  Waveform
3. Systemic Examination
CVS
Inspection / Palpation
Apex Parasternal Heave
Palpable Sounds                      Thrills
Auscultation
S1             S2                          Murmurs
Extra Heart Sounds
Other System
RS:                                PA:          CNS :
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ECHOCARDIOGRAPHIC ASSESSMENT OF HCM
Name: Age:                                             Sex:
Echocardiographic parameters:
M-mode:
LV:                     EDD-   ESD-          EF-                   FS-
Septal thickness
Posterior wall thickness 
RV:                      RVFWT                                      RVEDD
Mitral valve:
Aortic valve: LVOT diameter:
LA :
Tricuspid valve:
Pulmonary valve: 
          
RVOT :                                                 MPA:
2 D and DOPPLER HEMODYNAMIC ASSESSMENT:
Mitral inflow:
E-wave: Peak velocity - DT-
A-wave: Peak velocity - TVI-
E/A ratio:
TISSUE DOPPLER
Mitral annular:             E’ velocity-                                   A’ velocity-
E/E’ ratio:
SAM  Grade  :
MR :
Aortic Outflow:
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LVOT  GRADIENT: 
AORTIC  Peak velocity:
VTI:
IVRT:
IVCT:
Tricuspid inflow:
E-wave:        Peak velocity- DT-
A-wave:         Peak velocity-                                          TVI-
RT  interval 
RV Outflow
Pulmonary valve:  Peak velocity
RP interval 
RV IVRT
Pattern of Hypertrophy :
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                     PATIENT CONSENT FORM
STUDY TITLE :
Risk stratification of patients with Hypertrophic Cardiomyopathy  
and assessment of Biventricular diastolic function by pulse/tissue 
doppler echocardiographic imaging ”     
PARTICIPANT NAME : DATE:
AGE:             SEX:                                   I.P.NO. :
The details of the study have been provided to me in writing and explained 
to me in my own language.
I confirm that I have understood the purpose of  the above study. 
I have the opportunity to ask the question and all my questions 
and doubts have been answered to my complete satisfaction.
I understand that my participation in the study is voluntary and
that I am free to withdraw at any time without giving any reason, 
without my legal rights being affected.
I understand that investigator, the institution, regulatory 
authorities and the ethical committee will not need my 
permission to look at my health records both in respect to the 
current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study. I understand that 
my identity will not be revealed in any information released to 
third parties or  published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from 
this study. 
I hereby consent to,undergo complete physical examination ,and 
diagnostic tests including hematological, biochemical,
radiological and urine examinations
I have been given an information sheet giving details of the study .
I hereby consent to participate in the above study 
Signature of the Participant
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Information to Participants
Title: Risk Stratification Of Patients With Hypertrophic Cardiomyopathy And 
Assessment Of Biventricular   Diastolic Function By Pulse/Tissue Doppler 
Echocardiographic Imaging
Principal Investigator: DR.A.MURALIDHARAN
Co-Investigator(if any):
Name of Participant:
Site :   RGGGH& MMC, Chennai
You are invited to take part in this research/ study/procedures/tests. The information in 
this document is meant to help you decide whether or not to take part. Please feel free 
to ask if you have any queries or concerns.
What is the purpose of research?
Hypertrophic cardiomyopathy (HCM) is a genetically transmitted disease with 
broad morphologic and clinical spectrum. Patients with hypertrophic 
cardiomyopathy are mostly discovered during routine examination, because of ECG 
abnormalities, or when they become symptomatic. Echocardiography remains the 
corner stone for its diagnosis and classification.HCM is the most common cause of 
sudden death in young.Hence we aim to stratify the risk of SCD in HCM patients .
Left ventricular diastolic function in hypertrophic cardiomyopathy seems to be well 
studied but little is known about right ventricular diastolic function in hypertrophic 
cardiomyopathy. Right ventricular hypertrophy and elevated right ventricular end 
diastolic pressures have been reported in patients with hypertrophic 
cardiomyopathy. On the other hand the two ventricles are in anatomic and 
functional connection, hence the loadingconditions of one ventricle may affect the 
function of the other.Hence Biventricular diastolic function is evaluated using pulse 
and tissue doppler echocardiography. We have obtained permission from the 
Institutional Ethics Committee. 
The study design: It is a Prospective observational study 
Study Procedures The study involves  risk stratification of patients with 
hypertrophic    cardiomyopathy and assessment of biventricular   diastolic function 
by pulse/tissue doppler echocardiographic imaging
Confidentiality of the information obtained from you
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You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of India 
to view your data, if required.The information from this study, if published in 
scientific journals or presented at scientific meetings,will not reveal your identity.
How will your decision to not participate in the study affect you?
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken 
care of  and you will not loose any benefits to which you are entitled. 
Can you decide to stop participating in the study once you start?
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving 
any reasons. However, it is advisable that you talk to the research team prior to 
stopping the treatment/discontinuing of procedures etc.
Signature of Investigator                                           Signature  of  Participant  
Date :                                                
S.NO NAME AGE SEX LVEDD LVESD LVEF FS SEPTAL THICKNESS PW THICKNESS RVFWT RVEDD LV-PVE LV-PVA LV- E/A LV-DTE RV-PVE
1 abdul jalil 54 m 38 25 63 34 21 9 7 20 57 72 0.8 223 45
2 achuthan 36 m 47 32 61 32 16.4 9.6 6.7 26 86.6 54.4 1.6 148 72.6
3 arumugam 65 m 40 23 65 35 16.6 10.6 5.16 22.8 105 63.5 1.65 189 41.9
4 madhuram 52 m 41 27 64 34.2 18 10.5 9 16.6 76 69 1.1 155 69.9
5 malleswari 25 f 36 18 82 50 18.9 10.2 8.6 24.5 77.5 55.1 1.4 115 60
6 arulmoorthy 52 m 42 28 62 33 17.8 7.8 5.2 16.8 64.8 77.6 0.8 236 42.6
7 saravanan 37 m 46 22 80 52 16.8 8.8 5.7 27 88.5 48 1.8 118 53.8
8 usha 44 f 45 23 77 48 18.1 7.3 6.9 21.7 110 145 0.75 219 47.5
9 sankar 40 m 40 28 58 30 14 6.7 5.7 18.1 122 88 1.38 148 67.8
10 suresh 56 m 42 27 65 36 17.6 8.2 5.3 16.4 36 53 0.7 167 30
11 murugan 45 m 37 22 65 35 16.6 10.6 5.9 25.1 46.4 41.5 1.1 148 47.8
12 parameswari 60 f 44 24 75 45.5 16.3 6.8 5.7 21.8 99.1 65.6 1.5 266 55.8
13 govindasamy 50 m 45.8 27.5 69 40 21 11 8 22 188 76.4 2.4 135 62
14 rajivgandhi 38 m 46.7 33.2 57 28 15 6.2 7.7 24 57.5 41.5 1.4 148 64
15 ramachandran32 m 39 20 77 49 14.9 9 5.2 23 126 84.1 1.5 229 98.2
16 smriti 36 f 47 25 76 47 15.4 8.9 7.8 27.7 74.2 97.3 0.8 178 49.8
17 thirumoorthy 40 m 45 24 76 47 21.8 9.8 7.8 25 48.5 40.4 1.2 261 42.4
18 balu 52 m 42 25 70 40 16 9 5.3 18 83 112 0.7 130 40
19 anish 30 m 42 18 70 57 16.5 7.1 6.2 23 77 92 0.8 186 60
20 arulpandi 38 m 44 22 79 50 20 11.2 8.5 22.4 76.4 54.3 1.4 121 64
21 senthilkumar 37 m 47 29 68 38 18.8 8.1 5.7 17.6 62.8 79.6 0.78 256 46.8
22 sivakumar 40 m 47 21 82 54 18.8 10.1 6.7 17.8 93.5 51 1.8 121 55.8
23 sudha 30 f 35 23 63 34 17.1 8.3 7.9 19.8 109 155 0.7 229 45.5
24 sudhakar 42 m 43 28 64 35 13 6.7 6.7 17.1 112 68.4 1.6 148 69.8
25 krishnamoorthy 48 m 30 17 77 44 16.5 9.2 5.6 14.4 34 51 0.66 170 32
26 elumalai 42 m 39 22 73 44 15.5 10.3 5.6 23.2 47.8 42.5 1.1 144 49.2
27 shruti 26 f 44 21 80 52 16.7 6.5 5.4 22.7 98.6 63.4 1.5 262 53.7
28 kamal 33 m 44.7 27 69 39 22 12 7.6 24 178 76.2 2.3 128 66
29 lakshmipathy 45 m 45.8 31 61 32 13 6.6 7.2 22 54.3 42.7 1.3 145 60
30 ahamed 41 m 42 23 74 45 16.2 9.6 5.7 21.3 110 62.6 1.75 178 43
31 rajagopal 65 m 49 25 65 35 16.2 9.9 8.4 28.7 77.3 99.2 0.8 189 51.8
32 vellachi 55 f 35 24 65 35 20.7 9.6 8.2 24 46.4 41.5 1.1 271 40.3
33 venkatesh52 m 41 25 69 38 14 9 5.7 16 86 102 0.8 133 42
34 viji 22 f 32 18 65 35 14.5 7.2 6.7 25 78 99 0.8 182 62
35 saroja 33 f 46 24 77 48 22 10.1 6.8 22 59 74 0.8 212 43
36 joseph 28 m 47 23 79 51 16.9 9.3 6.3 28 89.9 53.2 1.7 152 71.7
37 jeagan 45 m 44 21 80 52 16.8 10.1 5.2 23.2 107 68.2 1.6 178 42.8
38 sundar 46 m 41 24 71 41 17 9.2 7 22 74 65 1.1 152 67.8
39 jyotikumar 32 m 39 17 84 56 18.6 9.8 8.2 22.5 73.5 52.5 1.4 120 62
40 sivan 30 m 44.2 27.2 68 38 20 9 7 21 176 74.2 2.4 132 64
RV-PVA RV-E/A RV-DTE MV-Ea MV-Aa TV-Ea TV-Aa FAMILY H/O SCD syncope NSVT-HOLTER SAM MR LVOT GR E/Ea Maron type RV-IVRT
48 0.9 243 3.3 6.9 45.3 48.5 x x 170/11.6 17.3 2 94
49.6 1.46 121 7.1 4.5 7.6 33.7 x x vpc,1stdegreeavblock Gr1 1+ 106/4.6 12 2 127
30.7 1.36 236 10.1 5.9 16.4 16.3 x x Gr2 1+ 138/7.62 10.3 4 170
65.5 1.06 202 4.3 6.6 5.9 8.4 vpc 150/9.4 17.6 3 139
34 1.7 202 6.7 4.9 16.8 15.5 108/4.8 11.6 4 240
32.5 1.3 240 6 8.1 7.5 12.7 106/4 12.6 1 68
33.5 1.6 246 8.5 4.1 8.5 4.1 110/5 10.4 2 102
34 1.4 192 4.8 7.7 12.7 23.4 x x nsvt Gr3 440/77 23 3 77
32.6 2.1 159 9.7 7.5 23.8 15.6 110/5 10.4 4 86
41 0.7 120 5 8 7 11 112/5 7.2 3 78
43.8 1.09 277 3.72 4.19 13.4 18.8 Gr2 140/7.87 12.4 3 140
41.2 1.3 302 3.3 5 14.3 11.1 vpcs Gr2 249/24.8 33 3 74
60 1.03 101 7.3 9.7 11 17 nsvt Gr3 2+ 331/43.7 25.7 4 134
40 1.6 223 4.3 6.6 8.7 16.3 84.4/2.85 13.37 4 248
119 0.8 115 6.1 9 15.3 26.1 x x nsvt Gr2 2+ 468/87.5 20.6 4 249
54 0.9 276 4.9 7.7 11.1 13.4 x nsvt Gr3 1+ 368/54 15.1 4 76
47.6 0.9 124 2.3 4.8 11 31 x 122/6 21 1 220
45 0.9 260 5.6 8.1 5.7 8.2 x vpcs Gr1 1+ 289/33 14.8 3 272
58 1 178 2.6 4.2 11 31 x nsvt Gr2 2+ 549/121 29.6 3 70
30 2.1 210 5.5 4.2 14.7 16.2 120/6 13.9 4 250
33.5 1.4 270 5 9.1 9.5 13.8 106/4.6 12.6 3 68
35.6 1.6 256 9.5 4.3 9.5 4.3 119/5.69 9.8 2 93
36 1.3 202 5.8 8.7 14.7 25.4 x x nsvt Gr3 463/85.6 18.8 3 67
35.6 1.9 169 10.7 9.5 21.8 18.6 120/5.7 10.5 4 88
42 0.7 110 6 8 9 13 104/4.3 3 78
41.8 1.2 274 3.42 4.1 12.7 17.5 Gr2 130/7 14 3 138
40.4 1.3 288 3.5 6 13.7 10.9 vpc Gr2 279/32 28 3 72
60 1.1 111 7.5 9.4 12 18 nsvt Gr3 2+ 351/49 24 4 138
45 1.3 211 4.2 6.9 8.3 16.6 94.4/3 13 4 232
31.6 1.3 228 11.1 5.6 16.6 17.3 x x Gr2 1+ 148/9 10.6 4 168
56 0.9 297 4.7 7.6 10.2 13 x nsvt Gr3 1+ 358/51.8 16.4 4 70
46.8 0.9 121 2.2 4.5 13 32 x 133/7 21 1 240
47 0.9 270 5.9 8.4 5.9 8.4 x vpcs Gr1 1+ 279/31 14.5 3 270
61 1 182 2.2 4.5 13 32 x nsvt Gr2 2+ 569/130 35 3 64
47 0.9 233 3.1 6.7 40.2 46.4 x x 176/12 19 2 98
48.3 1.5 124 6.7 4.2 7.2 31 x x vpc,1stdegreeavblock Gr1 1+ 103/4 13 2 123
28.9 1.5 239 10.6 5.6 16.2 16.3 x x Gr2 1+ 128/7 10 4 170
63.2 1.1 201 4.4 6.8 5.7 8.1 143/8 16.8 3 132
30 2 210 6.4 4.7 15.9 14.2 102/4 11.5 4 270
59 1.1 110 7.1 9.5 12 19 nsvt Gr3 2+ 343/50 24.8 4 137
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